CSIMarket Company Name, Ticker, Suppliers, else..
 
Sonoma Pharmaceuticals Inc   (NASDAQ: SNOA)
Other Ticker:  
 
 
Price: $2.8400 $0.20 7.576%
Day's High: $3.04 Week Perf: 7.17 %
Day's Low: $ 2.63 30 Day Perf: 7.98 %
Volume (M): 276 52 Wk High: $ 9.37
Volume (M$): $ 783 52 Wk Avg: $3.64
Open: $2.63 52 Wk Low: $2.44



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees 46
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals Inc is a healthcare company that focuses on developing, manufacturing, and marketing innovative pharmaceutical products. The company specializes in healthcare solutions for dermatological conditions and uses its proprietary technology to develop non-toxic and safe products. Sonoma Pharmaceuticals offers a range of products including wound care, eye care, dermatology, and animal healthcare products. The company aims to provide effective and affordable solutions for various medical conditions.


   Company Address: 5445 Conestoga Court Boulder 80301 CO
   Company Phone Number: 759-9305   Stock Exchange / Ticker: NASDAQ SNOA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV      % 
AMGN      % 
BMY      % 
LLY      % 
MRK      % 
VTRS      % 
• View Complete Report
   



Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc. Achieves Balanced Books and 6.59% Revenue Growth in Fiscal Q3 2024

As a financial journalist covering the healthcare sector, I closely monitor the financial results of companies like Sonoma Pharmaceuticals Inc. The recent fiscal third quarter results of Sonoma Pharmaceuticals Inc. have shown significant improvement compared to the previous year, as well as sequential growth from the prior financial reporting period.
One of the most notable achievements for Sonoma Pharmaceuticals Inc. in the fiscal third quarter of 2024 is reaching balanced books of $0.00 per share, compared to a loss of $-0.62 per share in the same period a year before. The revenue also saw a solid increase of 6.59% to $3.14 million, demonstrating the company's ability to drive growth despite challenges in the market.
Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc: Surprising Earnings Surge Amidst Revenue Slump



Sonoma Pharmaceuticals Inc, a major pharmaceutical preparations company, recently released its financial results for the second quarter of 2024. The report reveals a significant improvement in their earnings per share (EPS) compared to the previous year. However, the company experienced a decline in revenue compared to both the previous year and the previous financial reporting period. Additionally, inventory levels and accounts receivable have decreased, potentially indicating a slowdown in demand. This article aims to analyze and provide insights into the observed financial results of Sonoma Pharmaceuticals Inc.
Financial Performance Analysis:
In the second quarter of 2024, Sonoma Pharmaceuticals Inc achieved balanced books with an EPS of $0.00 per share. This shows a positive improvement from the previous year's EPS of -0.33 per share. However, when compared to the previous financial reporting period, there was no significant change. The company's ability to reach a balance suggests stabilization and strength in its financial performance.
Sonoma Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Plunges into Unexpected Revenue Collapse, Raises Concerns for Sonoma Pharmaceuticals Inc's Future



Sonoma Pharmaceuticals Inc, a company operating in the fiscal time-frame ending June 30, 2023, has released its latest financial results. While the company showed significant progress in certain areas, other aspects raised concerns. This article aims to interpret the financial results and analyze how they might impact Sonoma Pharmaceuticals Inc in the future.
Zero Gain per Share:
Sonoma Pharmaceuticals reached a break-even point, reporting a gain of $0.00 per share in comparison to a loss of $0.29 per share a year ago. This noticeable improvement from the previous year is likely a positive sign for investors. However, it is worth noting that the gain decreased significantly from the preceding quarter, where it stood at $1.24 per share. This volatility raises questions about the company's stability and growth prospects.
Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc Reports Phenomenal Earnings in Q4 2023 with Significant Profit Turnaround
Article: For the fiscal quarter spanning January 1 to March 31, 2023, Sonoma Pharmaceuticals Inc successfully transitioned from a period of losses to marking profitability. The company posted an Earnings Per Share (EPS) of $1.24, making a notable contrast to the EPS of -$0.95 reported during the same span a year prior. The figure also marks a significant improvement from the -$0.62 per share reported in the preceding period.


Introduction:
Sonoma Pharmaceuticals Inc, a major pharmaceutical preparations company, has experienced a significant turnaround in the first quarter of 2023. The company's earnings per share (EPS) turned positive, resulting in a profitable quarter compared to the previous year. Additionally, Sonoma Pharmaceuticals Inc witnessed substantial revenue growth during the same period. This article will delve into the financial highlights of Sonoma Pharmaceuticals Inc, exploring the factors behind its success and its future outlook.
Profitability and Earnings Performance:
During the January to March 31, 2023 timeframe, Sonoma Pharmaceuticals Inc achieved a remarkable turnaround in profitability. The company reported an EPS of $1.24 per share, a significant improvement from the negative EPS of $-0.95 posted in the same period the previous year. Moreover, the earnings per share turned positive from $-0.62, recorded in the prior reporting period. This positive development indicates a boost in Sonoma Pharmaceuticals Inc's financial health, resulting from effective cost management and operational strategies.






Sonoma Pharmaceuticals Inc's Segments
Human Care Product    82.62 % of total Revenue
Animal Care Product    11.23 % of total Revenue
Service And Royalty Service    6.15 % of total Revenue
Revenue Benchmark UNITED STATES    18.86 % of total Revenue
Revenue Benchmark Europe    42.08 % of total Revenue
Revenue Benchmark Asia    21.68 % of total Revenue
Revenue Benchmark Latin America    12.99 % of total Revenue
Revenue Benchmark Rest Of The World    4.39 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com